Targeting raised von Willebrand factor levels and macrophage activation in severe COVID-19: Consider low volume plasma exchange and low dose steroid
- 4 May 2020
- journal article
- letter
- Published by Elsevier BV in Thrombosis Research
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- DOACs and “newer” hemophilia therapies in COVID‐19: ReplyJournal of Thrombosis and Haemostasis, 2022
- Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive studyThe Lancet Infectious Diseases, 2020
- Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern ItalyPublished by Cold Spring Harbor Laboratory ,2020
- Severe COVID-19 infection associated with endothelial activationThrombosis Research, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- Effect of therapeutic plasma exchange on endothelial activation and coagulation-related parameters in septic shockCritical Care, 2020
- Low-volume plasma exchange and low-dose steroid to treat secondary hemophagocytic lymphohistiocytosis: A potential treatment for severe COVID-19?Current Medical Issues, 2020
- Rodenticidal hepatotoxicity: Raised plasma Von Willebrand factor levels predict in-hospital survival and preliminary report of the outcome of Von Willebrand factor reducing management protocolIndian Journal of Gastroenterology, 2019
- Plasma von Willebrand factor levels predict in-hospital survival in patients with acute-on-chronic liver failureIndian Journal of Gastroenterology, 2016